CD274 and cancer: A recent study conducted in Israel using electronic medical records from four Israeli cancer centers between the years 2016 and 2020 (N = 256, median follow-up of 22.3 months) have demonstrated a median rwOS of 12.5 (95% CI: 9.8–16.4) months and 20.4 [95% CI: 10.8–not reached (NR)] months in PD-1/PD-L1 inhibitor monotherapy and PD-1/PD-L1 inhibitor combination with chemotherapy group, respectively (31).